End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.82 CNY | -0.77% | -2.49% | +2.62% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.62% | 1.08B | - | ||
-12.45% | 79.57B | B+ | ||
+12.08% | 8.4B | B- | ||
+25.88% | 3.76B | B- | ||
-0.14% | 3.18B | B- | ||
+14.19% | 1.67B | - | ||
+0.56% | 1.64B | B | ||
-17.79% | 1.38B | C- | ||
-0.39% | 1.32B | - | ||
-5.20% | 1.24B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300119 Stock
- Ratings Tianjin Ringpu Bio-Technology Co.,Ltd.